What is KeyCorp's Estimate for IDXX Q3 Earnings?

Key Points

• KeyCorp estimates IDEXX Laboratories will report Q3 2026 EPS of $3.70 and maintains a “Sector Weight” rating. The firm forecasts FY2026 EPS of $14.77, compared with the broader consensus estimate of $14.81.
• IDEXX recently exceeded expectations, reporting quarterly EPS of $4.27 versus the $3.94 consensus, while revenue rose 9.7% year over year to $1.22 billion. Management’s FY2026 EPS guidance is $14.69–$14.94.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus rating and an average price target of $747, although IDXX shares opened at $520.31 and remain near their one-year low.

IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) - KeyCorp issued their Q3 2026 earnings per share estimates for shares of IDEXX Laboratories in a report released on Sunday, October 11th. KeyCorp analyst S. Dechert anticipates that the company will earn $3.70 per share for the quarter. KeyCorp currently has a "Sector Weight" rating on the stock. The consensus estimate for IDEXX Laboratories' current full-year earnings is $14.81 per share. KeyCorp also issued estimates for IDEXX Laboratories' Q4 2026 earnings at $3.34 EPS, FY2026 earnings at $14.77 EPS, Q1 2027 earnings at $3.93 EPS, Q2 2027 earnings at $4.61 EPS, Q3 2027 earnings at $4.22 EPS, Q4 2027 earnings at $3.81 EPS, FY2027 earnings at $16.58 EPS and FY2028 earnings at $18.74 EPS.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The business's revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS.

IDXX has been the subject of several other research reports. Citigroup boosted their target price on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Weiss Ratings raised shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research report on Thursday, October 8th. UBS Group increased their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Finally, Barclays lowered their price objective on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating for the company in a report on Tuesday, August 11th. Six equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $747.00.

IDEXX Laboratories Price Performance

Shares of IDXX stock opened at $520.31 on Wednesday. The firm has a market cap of $40.99 billion, a P/E ratio of 36.85, a P/E/G ratio of 2.80 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories has a 1-year low of $500.61 and a 1-year high of $769.98. The firm has a fifty day moving average of $536.72 and a two-hundred day moving average of $552.17.

Hedge Funds Weigh In On IDEXX Laboratories

A number of hedge funds have recently added to or reduced their stakes in the business. J. Stern & Co. LLP lifted its holdings in IDEXX Laboratories by 23,694.7% in the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after purchasing an additional 2,642,200 shares during the period. Bank of New York Mellon Corp bought a new position in IDEXX Laboratories in the 2nd quarter valued at about $628,223,000. Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories by 52.4% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 838,839 shares of the company's stock valued at $471,335,000 after buying an additional 288,471 shares during the period. Alyeska Investment Group L.P. increased its stake in IDEXX Laboratories by 97.3% during the 2nd quarter. Alyeska Investment Group L.P. now owns 401,082 shares of the company's stock valued at $211,146,000 after buying an additional 197,808 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its stake in IDEXX Laboratories by 93.4% during the 1st quarter. Montrusco Bolton Investments Inc. now owns 342,120 shares of the company's stock valued at $186,707,000 after buying an additional 165,188 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Activity

In related news, Director Lawrence D. Kingsley sold 2,203 shares of the company's stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the sale, the director directly owned 9,568 shares of the company's stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.79% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc NASDAQ: IDXX develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX's companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.